Why Some People Don't Lose Weight on Semaglutide

Semaglutide produces an average of 14–17% body weight loss in clinical trials. But averages obscure a wide range of individual responses — from people who lose over 25% to those who lose less than 5%. The reasons for sub-optimal response are identifiable, and most are addressable.

Biological non-responders: GLP-1 receptor variants

Approximately 5–15% of people appear to be partial or full non-responders to GLP-1 agonists. The most studied mechanism involves genetic variants in the GLP-1 receptor gene (GLP1R) that reduce receptor binding affinity or post-receptor signalling efficiency. If the receptor doesn't respond normally to the drug, the full appetite-suppressing and gastric emptying effects won't be achieved regardless of dose.

Evidence note:

A 2023 study in Cell Metabolism identified a common GLP1R variant (p.Asn2Asp) associated with significantly attenuated response to semaglutide in a large European cohort.

Diet quality still matters — appetite suppression isn't total

Semaglutide reduces appetite and portion sizes — but it doesn't eliminate hunger entirely, nor does it make highly palatable, calorie-dense food less rewarding. People who continue eating large portions of hyper-palatable food (ultra-processed food, high-sugar items) often find the caloric deficit created by semaglutide is insufficient. Semaglutide shifts the caloric equation; it doesn't rewrite it completely.

Evidence note:

The SCALE trial showed a mean 14.9% weight loss — which means a substantial proportion of participants lost significantly less than this. Diet composition was associated with outcomes in observational follow-up studies.

Muscle mass loss without adequate protein

Semaglutide doesn't selectively reduce fat — it reduces total caloric intake. In a caloric deficit without adequate protein intake, 25–40% of weight lost can be lean mass (muscle). Loss of muscle mass slows resting metabolic rate, potentially explaining why some people appear to plateau early or find the weight difficult to maintain. High protein intake (1.2–1.6g/kg bodyweight) during semaglutide use is mechanistically important.

Evidence note:

A 2023 analysis of SCALE participants found that those who lost the highest proportion of lean mass had significantly worse metabolic outcomes and lower physical function at end of study.

Psychological eating patterns aren't addressed

Semaglutide suppresses physiological hunger (the empty stomach feeling). It has limited effect on psychological eating: stress eating, reward eating, emotional eating, or habitual eating in the absence of physical hunger. People whose overeating is primarily driven by these psychological patterns often find that semaglutide addresses only part of their food intake, and results are correspondingly partial.

Evidence note:

This distinction is acknowledged in clinical guidelines — most obesity medicine specialists recommend combining GLP-1 pharmacotherapy with behavioural intervention for optimal outcomes.

Dose insufficiency — many people don't reach therapeutic dose

The SCALE trial used 2.4mg weekly — the high dose approved for obesity. Many patients (and some prescribers) interpret good results at 0.5mg or 1mg as a reason to stop titrating. The dose-response relationship is real: weight loss at 2.4mg is meaningfully greater than at 1mg. Stopping titration early due to 'good enough' progress or side effect concerns at intermediate doses means not reaching the compound's full potential.

Evidence note:

SCALE dose-response analyses confirm significant additional weight loss moving from 1mg to 2mg in the semaglutide obesity trials.

Weight regain after stopping

The most misunderstood 'failure' mode: stopping semaglutide and regaining weight. The STEP 4 withdrawal trial showed that ~67% of weight lost was regained within 1–2 years of stopping. This is not a failure of semaglutide — it's the expected outcome of withdrawing a treatment for a chronic condition. Obesity is a chronic disease; semaglutide treats it, but it doesn't cure it. Long-term or indefinite use is often required to maintain results.

Evidence note:

STEP 4 (New England Journal of Medicine, 2022): Patients who discontinued semaglutide after 20 weeks regained 6.9% body weight over the following year; those continuing maintenance lost an additional 7.9%.

Educational context only. This article is for research purposes. Semaglutide is a prescription medication. Any use should be under medical supervision.

Weight Loss Peptides Guides

→ Semaglutide Dosage Guide → Tirzepatide vs Semaglutide → How GLP-1 Agonists Work → Tesofensine Results → Best Peptides for Fat Loss (Ranked)→ Insulin, Appetite & Peptides